ES2331909T3 - Factor viii estabilizado con enlaces disulfuro modificados geneticamente. - Google Patents

Factor viii estabilizado con enlaces disulfuro modificados geneticamente. Download PDF

Info

Publication number
ES2331909T3
ES2331909T3 ES02737516T ES02737516T ES2331909T3 ES 2331909 T3 ES2331909 T3 ES 2331909T3 ES 02737516 T ES02737516 T ES 02737516T ES 02737516 T ES02737516 T ES 02737516T ES 2331909 T3 ES2331909 T3 ES 2331909T3
Authority
ES
Spain
Prior art keywords
factor viii
factor
mutant
polypeptide
fva
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02737516T
Other languages
English (en)
Spanish (es)
Inventor
John H. Griffin
Andrew J. Gale
Elizabeth D. Getzoff
Jean-Luc Pellequer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Application granted granted Critical
Publication of ES2331909T3 publication Critical patent/ES2331909T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
ES02737516T 2001-06-14 2002-06-14 Factor viii estabilizado con enlaces disulfuro modificados geneticamente. Expired - Lifetime ES2331909T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29857801P 2001-06-14 2001-06-14
US298578P 2001-06-14

Publications (1)

Publication Number Publication Date
ES2331909T3 true ES2331909T3 (es) 2010-01-20

Family

ID=23151124

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02737516T Expired - Lifetime ES2331909T3 (es) 2001-06-14 2002-06-14 Factor viii estabilizado con enlaces disulfuro modificados geneticamente.

Country Status (8)

Country Link
US (2) US7205278B2 (enExample)
EP (2) EP1421539B1 (enExample)
JP (2) JP4361786B2 (enExample)
AU (1) AU2002310438B2 (enExample)
CA (1) CA2450732A1 (enExample)
DE (1) DE60234193D1 (enExample)
ES (1) ES2331909T3 (enExample)
WO (1) WO2002103024A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002103024A2 (en) * 2001-06-14 2002-12-27 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
EP1502921A1 (en) * 2003-07-29 2005-02-02 ZLB Behring GmbH Recombinant mutated human factor VIII (FVIII) with improved stability
AU2004296768B2 (en) * 2003-12-03 2010-06-24 University Of Rochester Recombinant factor VIII having increased specific activity
US20060019893A1 (en) * 2004-07-02 2006-01-26 Genentech, Inc. Factor VIIa variants
KR101483917B1 (ko) * 2004-11-12 2015-01-16 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
WO2006108590A1 (en) * 2005-04-14 2006-10-19 Csl Behring Gmbh Modified coagulation factor viii with enhanced stability and its derivates
GB0514779D0 (en) * 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
US20100144620A1 (en) * 2006-11-16 2010-06-10 Crucell Holland B.V. Complementation of factor xi deficeincy by factor v mutants
KR101542752B1 (ko) 2006-12-22 2015-08-10 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 변형된 응고 인자
KR20100113478A (ko) * 2007-11-01 2010-10-21 유니버시티 오브 로체스터 증가된 안정성을 갖는 재조합 인자 ⅴⅰⅰⅰ
RU2528855C2 (ru) 2008-06-24 2014-09-20 Цсл Беринг Гмбх Модифицированный фактор виллебранда с удлиненным полупериодом существования in vivo, его применения и способы получения
JP5816097B2 (ja) * 2009-01-22 2015-11-18 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
TW201127957A (en) * 2009-10-30 2011-08-16 Agres Ltd Modified oil encapsulating proteins and uses thereof
AU2011208620B2 (en) 2010-01-22 2015-04-16 Novo Nordisk Health Care Ag Stable growth hormone compounds
SI2525834T1 (sl) 2010-01-22 2019-10-30 Novo Nordisk Healthcare Ag Rastni hormoni s podaljšano in vivo učinkovitostjo
JP2013532176A (ja) * 2010-07-15 2013-08-15 ノヴォ ノルディスク アー／エス 安定化させた第ｖｉｉｉ因子バリアント
WO2012010516A1 (en) * 2010-07-22 2012-01-26 Novo Nordisk Health Care Ag Growth hormone conjugates
EP2814502B1 (en) 2012-02-15 2017-09-13 CSL Behring GmbH Von willebrand factor variants having improved factor viii binding affinity
CA2873511A1 (en) 2012-05-17 2013-11-21 Ra Pharmaceuticals, Inc. Peptide and peptidomimetic inhibitors
KR20150132449A (ko) * 2013-03-15 2015-11-25 바이엘 헬스케어 엘엘씨 재조합 인자 viii 제제
CN105120887A (zh) 2013-04-05 2015-12-02 诺和诺德保健股份有限公司 生长激素化合物制剂
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
CA2929671A1 (en) * 2013-11-04 2015-05-07 The Regents Of The University Of California Therapy for treatment or prevention of conditions associated with bleeding or hypocoagulation
US10253088B2 (en) 2014-07-02 2019-04-09 CSL Behring Lengnau AG Modified von Willebrand Factor
CA2978374A1 (en) 2015-03-06 2016-09-15 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
KR20180012303A (ko) 2015-05-22 2018-02-05 체에스엘 베링 리컴비넌트 퍼실리티 아게 변형된 폰 빌레브란트 인자의 제조 방법
EP3297656B1 (en) 2015-05-22 2020-01-08 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
CN104974228B (zh) * 2015-06-15 2017-10-17 四川合泰新光生物科技有限公司 一种小分子多肽zy4及其应用
CA3010720A1 (en) 2016-01-07 2017-07-13 Csl Behring Recombinant Facility Ag Mutated truncated von willebrand factor
DK3400238T3 (da) 2016-01-07 2021-07-26 CSL Behring Lengnau AG Muteret von willebrand faktor
SG10201912360SA (en) 2016-11-11 2020-02-27 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
US11890327B2 (en) 2016-11-11 2024-02-06 CSL Behring Lengnau AG Truncated von Willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
JP7524071B2 (ja) * 2018-04-19 2024-07-29 スティヒティング ブイユー タンパク質のマクロ環化
EP3810647A4 (en) * 2018-04-26 2022-08-17 The University of North Carolina at Chapel Hill METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEMOPHILIA

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214033A (en) * 1983-03-31 1993-05-25 Scripps Clinic & Research Foundation Factor VIII coagulant polypeptides
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
SE8501050D0 (sv) 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
WO1986006101A1 (en) 1985-04-12 1986-10-23 Genetics Institute, Inc. Novel procoagulant proteins
US5198349A (en) 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US4853871A (en) * 1987-04-06 1989-08-01 Genex Corporation Computer-based method for designing stablized proteins
US5449759A (en) * 1987-05-16 1995-09-12 Somatogen, Inc. Hemoglobins with intersubunit desulfide bonds
US5827821A (en) * 1987-12-10 1998-10-27 The Burnham Institute Conformationally stabilized cell adhesion peptides
US5009889A (en) * 1987-12-31 1991-04-23 Oklahoma Medical Research Foundation Treatment of dysfunctional vascular endothelium using activated protein C
US4852871A (en) * 1988-12-02 1989-08-01 John Perko Hand exercise device
US5082767A (en) * 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
US5610137A (en) * 1990-12-20 1997-03-11 The Uab Research Foundation Transgenic, cross-linked hemoglobin
US5661008A (en) * 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5114148A (en) * 1991-07-09 1992-05-19 Liu Ming Zen Puzzle device
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US6180371B1 (en) 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5453937A (en) * 1993-04-28 1995-09-26 Immunex Corporation Method and system for protein modeling
US5747654A (en) * 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
DE4418635C2 (de) * 1994-05-27 1997-07-24 Immuno Ag Pharmazeutische Zusammensetzung zur Vorbeugung und Behandlung von Blutgerinnungsstörungen
US5681746A (en) * 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
US5543149A (en) * 1995-03-01 1996-08-06 Rubin; Stan M. Treatment for insect bites
US5935568A (en) 1995-05-18 1999-08-10 National Jewish Medical & Research Center Gene therapy for effector cell regulation
US5910481A (en) * 1995-11-13 1999-06-08 Immuno Ag Hybrid proteins with modified activity
US20040092442A1 (en) * 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6262238B1 (en) * 1997-01-14 2001-07-17 Roche Diagnostic, Gmbh Process for modifying the stability of antibodies
DE69836206T2 (de) 1997-02-07 2007-08-23 Merck & Co., Inc. Synthetische hiv gag gene
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
WO2002103024A2 (en) * 2001-06-14 2002-12-27 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds

Also Published As

Publication number Publication date
JP2008271975A (ja) 2008-11-13
US20070276128A1 (en) 2007-11-29
EP2110385A8 (en) 2010-06-02
CA2450732A1 (en) 2002-12-27
JP2005500831A (ja) 2005-01-13
US7928199B2 (en) 2011-04-19
WO2002103024A3 (en) 2004-03-18
WO2002103024A2 (en) 2002-12-27
US20030125232A1 (en) 2003-07-03
JP4361786B2 (ja) 2009-11-11
EP1421539A2 (en) 2004-05-26
US7205278B2 (en) 2007-04-17
EP1421539A4 (en) 2005-11-09
EP2110385A1 (en) 2009-10-21
DE60234193D1 (de) 2009-12-10
EP1421539B1 (en) 2009-10-28
AU2002310438B2 (en) 2008-05-01

Similar Documents

Publication Publication Date Title
ES2331909T3 (es) Factor viii estabilizado con enlaces disulfuro modificados geneticamente.
AU2002310438A1 (en) Stabilized proteins with engineered disulfide bonds
ES2235154T3 (es) Factor viii hibrido humano y porcino.
JP3701028B2 (ja) 高純度フォンビルブラント因子の入手方法
ES2434035T3 (es) Conjugados de polímero-factor von Willebrand
ES2238284T3 (es) Factor viii modificado.
ES2821832T3 (es) Modificación de FVIII dirigida al sitio
ES2364118T3 (es) Purificación de factor viii usando una resina de modo mixto o multimodal.
AU2009239641B2 (en) Factor IX conjugates with extended half-lives
EP1424344A1 (en) Modified cDNA factor VIII and its derivates
ES2221926T3 (es) Fracciones del factor von willebrand de elevado y bajo pesos moleculares.
ES2371038T3 (es) Péptidos y derivados peptídicos así como composiciones farmacéuticas que contienen los mismos.
ES2747815T3 (es) Preparación que comprende péptidos de factor VIII y factor von Willebrand
BRPI0109131B1 (pt) dna, vetor de expressão compreendendo o mesmo, fator viii modificado de porcino, seu processo de produção e composição terapêutica compreendendo o mesmo
ES2343681T3 (es) Antagonistas de interaccion de factor viii con una proteina relacionada con el receptor de lipoproteinas de baja densidad.
ES2319745T3 (es) Secuencias de acidos nucleicos y aminoacidos que codifican polipeptidos de factor viii de alto nivel de expresion, y metodos de uso.
ES2938890T3 (es) Proteínas de fusión de VWF glucosiladas con farmacocinética mejorada
ES2262340T3 (es) Purificacion del fibrinogeno de la leche mediante el uso de cromatografia de intercambio cationico.
ES2224245T3 (es) Purificacion del complejo factor viii mediante cromatografia de inmunoafinidad.
ES2299653T3 (es) Concentrado de un factor de von willebrand que contiene el factor viii, y procedimiento correspondiente.
AU2008202293A1 (en) Stabilized proteins with engineered disulfide bonds
EP1284290A1 (en) Increase of the expression levels of factor VIII by insertion of spliceable nucleotide sequences into factor VIII cDNA
US20220305089A1 (en) Stabilizing buffer for factor viii and vwf
EP1502921A1 (en) Recombinant mutated human factor VIII (FVIII) with improved stability
EP3785726A1 (en) Factor viii protein with increased half-life